Statins and nonalcoholic fatty liver disease: necessarily and safety

Abstract

Long time statins remain treatment of choice among hypolipidemic agents, used for dyslipidemia correction during atherosclerotic vascular disease. However manyyears remains open a question of possibility, and the main thing, efficiency and safety of statins usage for nonalcoholic fatty liver disease. Tens of studies were conducted to identify ratio between risk of alanine aminotransferase and aspartate transaminase including double blind and placebo controlled, statins should be considered not only as possible but essential and safe solution to decrease level of total cholesterol,LDL-C: so decrease level of cardiovascularevents and levels of hepatic enzymes.